{
  "id": 11015583,
  "title": "Why is Sagimet Biosciences stock rallying today?",
  "url": "https://urgent.news/2026/09/30/why-is-sagimet-biosciences-stock-rallying-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T19:32:35.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-sagimet-biosciences-stock-rallying-today-93CH-4925769"
  },
  "original_language": "en",
  "account": "Sagimet Biosciences stock surged 3.5% today after the company unveiled promising long-term efficacy data for its oral fatty acid synthase inhibitor, denifanstat, used in treating acne. The data came from a Phase 3 clinical trial conducted by Ascletis BioScience Co. Ltd. in China. The study showed a 57% treatment-success rate after 52 weeks, with acne lesions decreasing by 72% and inflammatory lesions declining 77%. Participants remained in good health during the trial with no serious adverse events or permanent discontinuations attributed to the drug. Simultaneously, Sagimet announced a significant capital raise, selling approximately $115 million in Series A common stock and pre-funded warrants. The company plans to use the funds for a Phase 3 trial in acne, pre-launch activities, and advancing its TVB-3567 program. The U.S. AURORA Phase 3 trial is set to begin in October, enrolling around 800 patients aged 12 and over. The positive market sentiment, driven by lower-than-expected inflation data, helped the stock pull back slightly from its intraday high. Analysts maintain a moderate buy rating on the stock, reflecting confidence in the denifanstat development program as it approaches a crucial clinical milestone.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}